Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease

CONCLUSIONS: Compared to clopidogrel + low dose aspirin, the use of rivaroxaban 2.5 mg twice daily + low dose aspirin reduced the risk of MACE, CV death and stroke including ischemic stroke in patients with or at high risk for chronic CAD and/or PAD. These benefits of rivaroxaban 2.5 mg twice daily + low dose aspirin compared to clopidogrel + low-dose aspirin appear to be achieved without significantly increasing patients' risk of moderate-to-severe including ICH or fatal bleeding.PMID:34641745 | DOI:10.1080/03007995.2021.1991294

Source: Current Medical Research and Opinion - October 13, 2021 Category: Research Authors: Craig I Coleman Akshay A Kharat Brahim Bookhart William L Baker Source Type: research